CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 36 enrolled
Drug / intervention
(Arthrocentesis followed by i-PRF +HA)combination
Likely dose
(Arthrocentesis followed by i-PRF +HA) 1 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06446843
NCT06446843N/ACompleted

Assessment of Injectable Platelet-rich Fibrin With Hyaluronic Acid Versus Hyaluronic Acid in Management of Temporomandibular Joint Internal Derangement

Cairo University·interventional·Posted Jun 6, 2024·Updated Apr 9, 2025

In Brief

A clinical study evaluating (Arthrocentesis followed by i-PRF +HA) for Internal Derangement. Completed, enrolled 36 participants across 1 site.

Detailed Summary

Injectable PRF technology, according to literature evidence, ensures the release of growth factors over time which play a major role in the release of regenerative factors for tissue repair after injection, while HA is an anti-inflammatory medication that can provide rapid relief from pain and inflammation in joints. It is a major natural component of synovial fluid that plays an important role in lubrication of synovial tissues However, its effect is typically temporary, and it doesn\'t promote tissue healing or regeneration. For this reason, this protocol has been designed with the aim to investigate whether injection in the injection i- pRF with HA can achieve the same improvements of pain and function, compare this technique with arthrocentesis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesEgypt
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedJun 6, 2024
Enrollment StartSep 18, 2024
Primary CompletionMar 25, 2025
Study CompletionApr 1, 2025
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.1 years ago

Interventions

(Arthrocentesis followed by i-PRF +HA)combination

Intra-articular I-PRF with HA will be injected in the joint,1 ml of I-PRF will be injected inside the joint, Then from 25mg/ml of HA , 1ml will be injected into the superior joint space